AUTHOR=Ahmed Nausheen , Wesson William , Mushtaq Muhammad Umair , Bansal Rajat , AbdelHakim Haitham , Bromert Sarah , Appenfeller Allison , Ghazal Batool Abu , Singh Anurag , Abhyankar Sunil , Ganguly Siddhartha , McGuirk Joseph , Abdallah Al-Ola , Shune Leyla 

TITLE=“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy

JOURNAL=Frontiers in Oncology

VOLUME=Volume 13 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1206715

DOI=10.3389/fonc.2023.1206715

ISSN=2234-943X

ABSTRACT=• Manufacturing limitations led to limited access to ide-cel production slots in 2021.Amongst patients on the waitlist in 2021, 40% did not receive a production slot.• Median time from consultation for CAR-T to secure a production slot in 2021 was 1 month (range 0-23). Twenty percent of those who collected received a production slot beyond 6 months from the initial consultation.• Mortality is higher in RRMM patients who did not receive BCMA CAR-T, likely reflecting the effectiveness of BCMA CAR-T and stringent patient selection for limited CAR-T slots.